US 11306155
Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 11306155 (Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K39/3955, A61P